233 related articles for article (PubMed ID: 30703376)
21. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment.
He S; Chu X; Wu Y; Jiang J; Fang P; Chen Y; Liu Y; Qiu Z; Xiao Y; Li Z; Pan D; Zhang Q; Xie H; Xing S; Feng F; Liu W; Guo Q; Zhao L; Yang P; Sun H
J Med Chem; 2023 Jul; 66(14):9537-9560. PubMed ID: 37409679
[TBL] [Abstract][Full Text] [Related]
22. Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
Tavares TS; Hofman J; Lekešová A; Želazková J; Wsól V
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114555
[TBL] [Abstract][Full Text] [Related]
23. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
24. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
25. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
26. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and without Down syndrome.
Quiñones-Lombraña A; Ferguson D; Hageman Blair R; Kalabus JL; Redzematovic A; Blanco JG
Pharm Res; 2014 Jul; 31(7):1644-55. PubMed ID: 24562808
[TBL] [Abstract][Full Text] [Related]
27. Carbonyl reduction pathway in hepatic in vitro metabolism of anthracyclines: Impact of structure on biotransformation rate.
Piska K; Jamrozik M; Koczurkiewicz-Adamczyk P; Bucki A; Żmudzki P; Kołaczkowski M; Pękala E
Toxicol Lett; 2021 May; 342():50-57. PubMed ID: 33581289
[TBL] [Abstract][Full Text] [Related]
28. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
29. Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters.
Morell A; Budagaga Y; Vagiannis D; Zhang Y; Laštovičková L; Novotná E; Haddad A; Haddad M; Portillo R; Hofman J; Wsól V
Arch Toxicol; 2022 Dec; 96(12):3265-3277. PubMed ID: 35972551
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a highly specific monoclonal antibody against human aldo-keto reductase AKR1C3.
Liu J; He P; Lin L; Zhao Y; Deng W; Ding H; Li Q; Wang Z
Steroids; 2019 Mar; 143():73-79. PubMed ID: 30639543
[TBL] [Abstract][Full Text] [Related]
31. Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids.
Giménez-Dejoz J; Weber S; Fernández-Pardo Á; Möller G; Adamski J; Porté S; Parés X; Farrés J
Chem Biol Interact; 2019 Jul; 307():186-194. PubMed ID: 31028727
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.
Sorf A; Novotna E; Hofman J; Morell A; Staud F; Wsol V; Ceckova M
Biochem Pharmacol; 2019 May; 163():290-298. PubMed ID: 30826329
[TBL] [Abstract][Full Text] [Related]
33. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
34. Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis.
Rižner TL; Penning TM
Pharmacol Res; 2020 Feb; 152():104446. PubMed ID: 31546014
[TBL] [Abstract][Full Text] [Related]
35. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ; Wangtrakuldee P; Penning TM
J Steroid Biochem Mol Biol; 2022 Jul; 221():106121. PubMed ID: 35489629
[TBL] [Abstract][Full Text] [Related]
37. In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.
Plavša JJ; Řezáčová P; Kugler M; Pachl P; Brynda J; Voburka Z; Ćelić A; Petri ET; Škerlová J
Acta Crystallogr F Struct Biol Commun; 2018 May; 74(Pt 5):300-306. PubMed ID: 29717998
[TBL] [Abstract][Full Text] [Related]
38. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
39. Overview of AKR1C3: Inhibitor Achievements and Disease Insights.
Liu Y; He S; Chen Y; Liu Y; Feng F; Liu W; Guo Q; Zhao L; Sun H
J Med Chem; 2020 Oct; 63(20):11305-11329. PubMed ID: 32463235
[TBL] [Abstract][Full Text] [Related]
40. Role of Human Aldo-Keto Reductases in the Metabolic Activation of the Carcinogenic Air Pollutant 3-Nitrobenzanthrone.
Murray JR; Mesaros CA; Arlt VM; Seidel A; Blair IA; Penning TM
Chem Res Toxicol; 2018 Nov; 31(11):1277-1288. PubMed ID: 30406992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
